These findings suggest that the identified genes, particularly CDC20, H2AX, H3C13, HK2, and ITGB4, may serve as potential therapeutic targets for overcoming drug resistance in cholangiocarcinoma. The gene discussed is H2AX; the disease is cholangiocarcinoma.